期刊文献+

我院2006-2010年抗糖尿病药物应用分析 被引量:8

Utilization analysis of anti-diabetic drugs in our hospital during 2006-2010
暂未订购
导出
摘要 目的:分析北京医院抗糖尿病药的应用情况,为临床合理用药提供参考。方法:对卫生部北京医院2006–2010年抗糖尿病药物的种类、用量、销售金额、用药频度、日均费用等进行分析。结果:我院口服抗糖尿病药的销售金额占抗糖尿病药总金额的70%,其中,以α-葡萄糖苷酶抑制剂所占比例最高,胰岛素类约占30%;阿卡波糖、二甲双胍、诺和灵30R的DDDs较高,临床较为常用;二甲双胍、格列美脲、格列喹酮的DDC较低;噻唑烷二酮类药物的销售金额和DDDs逐年下降,其他药品的销售金额和DDDs均呈上升趋势,DDC逐年下降。瑞格列奈、那格列奈、甘精胰岛素的排序比值较低。结论:我院2006–2010年抗糖尿病药物的使用品种相对稳定,基本满足临床安全、经济、有效用药的需求。 Objective: To analyze the application situation of antidiabetic drugs in our hospital to provide reference for clinical rational drug use. Methods: The variety, amount, consumption sum, DDDs and average daily cost of antidiabetic drugs used in our hospital during 2006 - 2010 were analyzed retrospectively. Results: Sales amount of oral antidiabetic drugs accounted for 70% of the total amount of antidiabetic drugs. The sales amount of a-glucosidase inhibitor was the largest and the sales amount of insulin accounted for about 30% of the total amount of antidiabetic drugs. The values of DDDs of acarbose, metformin and Novolin 30R were higher than that of other antidiabetic drugs due to more common use in clinic. The values of DDC of metformin, glimepiride,gliquidone were lower. Exception for the decrease in the sales amount and DDDs of thiazolidinediones, the sales amount and DDDs of other antidiabetic drugs showed an upward trend. The ratios of consumption sum sequence to DDDs sequence of repaglinide, nateglinide and the insulin glargine were smaller. Conclusion: The oral antidiabetic drugs used in our hospital during 2006 - 2010 were basically stable in respect of varieties, which could meet the needs of rational drug use.
出处 《中国药物应用与监测》 CAS 2013年第1期38-41,共4页 Chinese Journal of Drug Application and Monitoring
关键词 抗糖尿病药物 销售金额 用药频度 日均费用 Antidiabetic drug Consumption sum DDDs DDC
  • 相关文献

参考文献13

二级参考文献131

共引文献181

同被引文献56

  • 1郭丰广,郝吉福,孝建华,李菲,宋涛,孙中东.抗糖尿病药物研究进展[J].泰山医学院学报,2008,29(3):234-237. 被引量:5
  • 2张为.2001年~2004年7月我院口服降糖药利用分析[J].中国药房,2005,16(5):364-365. 被引量:20
  • 3陈新谦,金有豫,汤光.新编药物学[M].17版.北京:人民卫生出版社,2011:3465.
  • 4陈新谦,金有豫,汤光.新编药物学[M].16版.北京:人民卫生出版社,2011:95.
  • 5Freeman JS. A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes meUitus[J]. Mayo Clin Proc, 2010, 85(12 Suppl): S5-S14.
  • 6Liao EP. Management of type 2 diabetes: new and future developments in treatment[J]. Am J Med, 2012, 125(10): S2-S3.
  • 7Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China[J]. N Engl J Med, 2010, 362(12): 1090- 1101.
  • 8Qaseem A, Humphrey LL, Sweet DE, et al. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians[J]. Ann Intern Med, 2012, 156 (3): 218-231.
  • 9Drucker DJ, Nauck MA.The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inbibitors in type 2 diabetes[J]. Lancet, 2006, 368(9548): 1696-1705.
  • 10Gallwitz B, Guzman J, Dotta F, et aL Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure(EUREXA): an open- label, randomised controlled trial[J]. Lancet, 2012, 379(9833): 2270-2278.

引证文献8

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部